Lemmens G - Search Results

1

Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.

Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D. Dewerchin M, et al. Among authors: lemmens g. Thromb Haemost. 1992 Aug 3;68(2):170-9. Thromb Haemost. 1992. PMID: 1412163

2

K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.

Collen D, Nelles L, De Cock F, Lemmens G, Van Coetsem T, Demarsin E, Lijnen HR. Collen D, et al. Among authors: lemmens g. Thromb Res. 1992 Feb 1;65(3):421-38. doi: 10.1016/0049-3848(92)90172-7. Thromb Res. 1992. PMID: 1631805

3

Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system.

Lijnen HR, Silence J, Lemmens G, Frederix L, Collen D. Lijnen HR, et al. Among authors: lemmens g. Thromb Haemost. 1998 Jun;79(6):1171-6. Thromb Haemost. 1998. PMID: 9657444

4

Modulation of cell-associated plasminogen activation by stromelysin-1 (MMP-3).

Ugwu F, Lemmens G, Collen D, Lijnen HR. Ugwu F, et al. Among authors: lemmens g. Thromb Haemost. 1999 Sep;82(3):1127-31. Thromb Haemost. 1999. PMID: 10494776

5

Matrix metalloproteinase deficiencies do not impair cell-associated fibrinolytic activity.

Ugwu F, Lemmens G, Collen D, Lijnen HR. Ugwu F, et al. Among authors: lemmens g. Thromb Res. 2001 Apr 1;102(1):61-9. doi: 10.1016/s0049-3848(01)00218-3. Thromb Res. 2001. PMID: 11323016

6

An alpha-mercaptoacrylic acid derivative (PD150606) inhibits selective motor neuron death via inhibition of kainate-induced Ca2+ influx and not via calpain inhibition.

Van den Bosch L, Van Damme P, Vleminckx V, Van Houtte E, Lemmens G, Missiaen L, Callewaert G, Robberecht W. Van den Bosch L, et al. Among authors: lemmens g. Neuropharmacology. 2002 Apr;42(5):706-13. doi: 10.1016/s0028-3908(02)00010-2. Neuropharmacology. 2002. PMID: 11985829

7

Minocycline delays disease onset and mortality in a transgenic model of ALS.

Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Van Den Bosch L, et al. Among authors: lemmens g. Neuroreport. 2002 Jun 12;13(8):1067-70. doi: 10.1097/00001756-200206120-00018. Neuroreport. 2002. PMID: 12060810

8

Immunohistochemical staining of ras oncogene product in neoplastic and non-neoplastic mesothelial tissues: immunoreactivity for N-ras and lack of immunohistochemical staining for Ha-ras and K-ras.

Ramael M, Deblier I, Eerdekens C, Lemmens G, Jacobs W, Van Marck E. Ramael M, et al. Among authors: lemmens g. J Pathol. 1993 Apr;169(4):421-4. doi: 10.1002/path.1711690406. J Pathol. 1993. PMID: 8501538

9

Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment.

Derave W, Van Den Bosch L, Lemmens G, Eijnde BO, Robberecht W, Hespel P. Derave W, et al. Among authors: lemmens g. Neurobiol Dis. 2003 Aug;13(3):264-72. doi: 10.1016/s0969-9961(03)00041-x. Neurobiol Dis. 2003. PMID: 12901841

10

Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium.

Ramael M, Lemmens G, Eerdekens C, Buysse C, Deblier I, Jacobs W, van Marck E. Ramael M, et al. Among authors: lemmens g. J Pathol. 1992 Dec;168(4):371-5. doi: 10.1002/path.1711680406. J Pathol. 1992. PMID: 1484318

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

95 results

Search Page

Filters